BioMarin CFO Departs, New CFO Appointed
Ticker: BMRN · Form: 8-K · Filed: Aug 1, 2025 · CIK: 1048477
| Field | Detail |
|---|---|
| Company | Biomarin Pharmaceutical INC (BMRN) |
| Form Type | 8-K |
| Filed Date | Aug 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, cfo, personnel
Related Tickers: BMRN
TL;DR
BioMarin's CFO is out, new one in. Effective Aug 1.
AI Summary
BioMarin Pharmaceutical Inc. announced on July 30, 2025, the departure of its Chief Financial Officer, Jeffrey Robert, effective August 1, 2025. The company also announced the appointment of Brad Miller as the new CFO, also effective August 1, 2025. This transition is part of the company's ongoing executive leadership changes.
Why It Matters
A change in Chief Financial Officer can impact investor confidence and the company's financial strategy, potentially affecting stock performance.
Risk Assessment
Risk Level: medium — Executive leadership changes, especially in key financial roles, can introduce uncertainty and signal underlying issues or strategic shifts.
Key Players & Entities
- BioMarin Pharmaceutical Inc. (company) — Registrant
- Jeffrey Robert (person) — Departing Chief Financial Officer
- Brad Miller (person) — Appointed Chief Financial Officer
- July 30, 2025 (date) — Date of Report
- August 1, 2025 (date) — Effective date of CFO changes
FAQ
Who is the departing Chief Financial Officer of BioMarin Pharmaceutical Inc.?
Jeffrey Robert is the departing Chief Financial Officer of BioMarin Pharmaceutical Inc.
When is the departure of Jeffrey Robert effective?
The departure of Jeffrey Robert is effective August 1, 2025.
Who has been appointed as the new Chief Financial Officer?
Brad Miller has been appointed as the new Chief Financial Officer.
When is Brad Miller's appointment as CFO effective?
Brad Miller's appointment as CFO is effective August 1, 2025.
What is the date of the report for this 8-K filing?
The date of the report for this 8-K filing is July 30, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 1, 2025 by Jeffrey Robert regarding BIOMARIN PHARMACEUTICAL INC (BMRN).